STEP HFpEF trial design and baseline characteristics

21 May 2023 (11:39 - 11:51)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

4 More presentations in this session

Presentation thumbnail

PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

Doctor R. Mentz (Durham, US)

Presentation thumbnail

A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

Doctor M. Vaduganathan (Boston, US)

Presentation thumbnail

DAPA-RESIST clinical trial - Dapagliflozin versus metolazone in heart failure with diuretic resistance

Doctor R. Campbell (Glasgow, GB)

Presentation thumbnail

Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial

Professor A. Voors (Groningen, NL)

Access the full session

Session thumbnail

Late breaking clinical trials: medical therapy

The Event

Event poster

Heart Failure 2023

21 May 2023 11:39 CET

You may be interested in

Congress Presentation

STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity

Congress Presentation

What's the next step in HFpEF?

Congress Presentation

The benefits of weight loss in heart failure: is it the weight loss or the drug?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources